Cellectis S.A. (CLLS) Rating Increased to Sell at BidaskClub
Cellectis S.A. (NASDAQ:CLLS) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Wednesday.
A number of other brokerages also recently commented on CLLS. Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Cellectis in a research note on Saturday, June 3rd. Finally, Jefferies Group LLC restated a “buy” rating and issued a $47.00 target price on shares of Cellectis in a research note on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $41.80.
Shares of Cellectis (CLLS) opened at 24.76 on Wednesday. The firm’s market capitalization is $887.94 million. The company’s 50 day moving average is $24.59 and its 200-day moving average is $23.72. Cellectis has a one year low of $16.09 and a one year high of $28.77.
WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/25/cellectis-s-a-clls-rating-increased-to-sell-at-bidaskclub.html.
Large investors have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. boosted its stake in Cellectis by 27.6% in the second quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after buying an additional 44,100 shares during the period. Vident Investment Advisory LLC boosted its stake in Cellectis by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock worth $1,224,000 after buying an additional 8,496 shares during the period. Balyasny Asset Management LLC acquired a new stake in Cellectis during the second quarter worth $719,000. Eqis Capital Management Inc. boosted its stake in Cellectis by 27.2% in the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock worth $276,000 after buying an additional 2,287 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after buying an additional 5,435 shares during the period. 16.06% of the stock is currently owned by institutional investors.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Stock Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related stocks with our FREE daily email newsletter.